News Novo Nordisk spends priority voucher on Wegovy filing Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.
News Data sets up phase 3 trials for Novo's amycretin in diabetes Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.
News Disappointment as Novo's oral GLP-1 fails in Alzheimer's GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.
News Waltz dances into direct-to-employer sales of obesity drugs Waltz Health is planning to disrupt the weight-loss therapy market in the US with a new direct-to-employer sales channel.
News Agios shares slump on sickle cell disease data Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.
News Novo Nordisk cuts Wegovy price ahead of TrumpRx launch Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.
News ASH: AstraZeneca's dual-wielding CAR-T shows promise AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
